n and immune responses, which play important roles in the chronic inflammation associated with the development of skin symptoms in psoriasis.US FDA
Health CanadaCalcipotriene 0.005% + betamethasone dipropionate 0.064% topical suspension
Taclonex®
Leo Pharma Inc.An expanded indication was granted for this topical combination treatment for plaque psoriasis of the scalp in patients 12-17 years of age. It is the first indication for adolescent patients aged ≥12 years with scalp plaque psoriasis among commercially available treatments.US FDAMethotrexate SC injection
Rasuvo™
Medac PharmaApproval was granted to this SC injectable methotrexate therapy delivered in an auto-injector for rheumatoid arthritis, polyarticularcourse juvenile idiopathic arthritis, and psoriasis.US FDA
Psoriatic Arthritis
银屑病性关节炎
Apremilast tablets
Otezla®
Celgene CorporationApproval was granted to the first oral therapy for the treatment of adults with active psoriatic arthritis (PsA). Apremilast is an oral small molecule inhibitor of PDE4 specific for cyclic adenosine monophosphate (cAMP). PDE4 inhibition results in increased intracellular cAMP levels, thereby suppressing immune responses.US FDARosacea（玫瑰痤疮）European Commission:
Brimonidine 3 mg/g gel
Mirvaso®
Galderma International
Health Canada:
Brimonidine tartrate 0.33% topical gel
Onreltea®
Galderma Canada Inc.This alpha-adrenergic receptor agonist received approval for the topical treatment of facial erythema (redness) of rosacea in adults ≥18 years of age. It is not indicated for the treatment of inflammatory lesions (papules and pustules). Brimonidine constricts dilated facial blood vessels to reduce the redness of rosacea. This drug has a rapid onset of action, with effects occurring as quickly as 30 minutes after application and lasting up to 12 hours. Brimonidine tartrate 0.33% gel (Mirvaso®) was US FDA approved in August of 2013.European Commission
Health CanadaIvermectin 1% cream
Soolantra®
Galderma Laboratories, L.P.Ivermectin 1% cream was approved for the once-daily topical treatment of inflammatory lesions, or bumps and pimples, of rosacea. The exact cause of rosacea is unknown, but multiple triggers have been implicated. Recent evidence suggests that rosacea may be caused by the over-proliferation of Demodex mites in the skin. Ivermectin has both anti-inflammatory and antiparasitic activities.US FDAUrticaria（荨麻疹）Omalizumab SC injection
Xolair®
Genentech, Inc. NovartisOmalizumab (a recombinant humanized monoclonal antibody that blocks the high-affinity Fc receptor of immunoglobulin E) was approved for the treatment of chronic idiopathic urticaria (CIU), also referred to as chronic spontaneous urticaria (CSU). The new use (already approved for asthma) is for patients ≥12 years of age who remain symptomatic despite H1-antihistamine therapy. Treatment is not indicated for other forms of urticaria (hives).European Commission
Health Canada
US FDA |
